Table S5. Baseline characteristics and frequency of outcomes of the study population according to CKD stages

| **Characteristic** | **G3a**, N = 4,7211 | **G3b**, N = 2,2071 | **G4**, N = 5911 |
| --- | --- | --- | --- |
| **Sex** |  |  |  |
| Female | 2,709 (57.4%) | 1,102 (49.9%) | 296 (50.1%) |
| Male | 2,012 (42.6%) | 1,105 (50.1%) | 295 (49.9%) |
| **Age (years)** |  |  |  |
| Mean (SD) | 73.1 (9.9) | 76.0 (10.2) | 73.9 (11.8) |
| Median (IQR) | 74.0 (67.0 - 80.0) | 77.0 (70.0 - 83.0) | 75.0 (67.0 - 83.0) |
| Range | 23.0 - 97.0 | 26.0 - 97.0 | 23.0 - 95.0 |
| **Hypertension** | 2,850 (60.4%) | 1,295 (58.7%) | 341 (57.7%) |
| **Diabetes Mellitus** | 1,171 (24.8%) | 521 (23.6%) | 153 (25.9%) |
| **Persistent albuminuria categories** |  |  |  |
| A1 | 3,278 (69.4%) | 1,302 (59.0%) | 192 (32.5%) |
| A2 | 1,158 (24.5%) | 632 (28.6%) | 228 (38.6%) |
| A3 | 285 (6.0%) | 273 (12.4%) | 171 (28.9%) |
| **CKD KDIGO classification** |  |  |  |
| Moderately increased risk | 3,278 (69.4%) | 0 (0.0%) | 0 (0.0%) |
| High risk | 1,158 (24.5%) | 1,302 (59.0%) | 0 (0.0%) |
| Very high risk | 285 (6.0%) | 905 (41.0%) | 591 (100.0%) |
| **Serum Creatinine (mg/dL)** |  |  |  |
| Mean (SD) | 1.2 (0.2) | 1.5 (0.2) | 2.3 (0.5) |
| Median (IQR) | 1.1 (1.0 - 1.3) | 1.5 (1.3 - 1.7) | 2.3 (1.9 - 2.6) |
| Range | 0.8 - 1.9 | 1.1 - 2.4 | 1.5 - 3.9 |
| **eGFR using CKD-EPI, ml/min/1.73m2** |  |  |  |
| Mean (SD) | 52.5 (3.9) | 38.8 (4.2) | 24.2 (4.1) |
| Median (IQR) | 52.6 (49.4 - 55.6) | 39.3 (35.3 - 42.4) | 24.7 (21.2 - 27.7) |
| Range | 45.0 - 60.0 | 30.0 - 45.0 | 15.0 - 30.0 |
| **Albumin-to-creatinine ratio, mg/g** |  |  |  |
| Mean (SD) | 198.0 (3,039.8) | 302.6 (3,386.3) | 451.7 (1,109.7) |
| Median (IQR) | 10.8 (3.9 - 41.5) | 20.3 (5.3 - 100.1) | 127.2 (17.7 - 405.2) |
| Range | 0.0 - 137,672.1 | 0.0 - 144,870.6 | 0.1 - 18,259.2 |
| **Urine Albumin (mg/ml)** |  |  |  |
| Mean (SD) | 5.5 (21.8) | 10.0 (31.4) | 25.0 (48.8) |
| Median (IQR) | 0.7 (0.2 - 2.4) | 1.3 (0.3 - 5.8) | 7.4 (1.3 - 20.9) |
| Range | 0.0 - 548.0 | 0.0 - 658.0 | 0.0 - 383.0 |
| **Urine Creatinine (mg/dl)** |  |  |  |
| Mean (SD) | 72.9 (47.9) | 71.3 (46.0) | 72.0 (50.7) |
| Median (IQR) | 62.4 (40.4 - 88.1) | 64.8 (43.0 - 85.0) | 65.3 (44.6 - 85.0) |
| Range | 0.1 - 438.3 | 0.8 - 620.1 | 0.7 - 722.1 |
| **Death at 2 years** | 282 (6.0%) | 230 (10.4%) | 128 (21.7%) |
| **Outcome at 2 years** |  |  |  |
| Alive w/o Kidney Failure | 4,432 (93.9%) | 1,965 (89.0%) | 445 (75.3%) |
| Death w/o Kidney Failure | 263 (5.6%) | 206 (9.3%) | 94 (15.9%) |
| Kidney Failure | 26 (0.6%) | 36 (1.6%) | 52 (8.8%) |
| **Death at 5 years** | 755 (16.0%) | 555 (25.1%) | 229 (38.7%) |
| **Outcome at 5 years** |  |  |  |
| Alive w/o Kidney Failure | 3,947 (83.6%) | 1,622 (73.5%) | 311 (52.6%) |
| Death w/o Kidney Failure | 717 (15.2%) | 504 (22.8%) | 179 (30.3%) |
| Kidney Failure | 57 (1.2%) | 81 (3.7%) | 101 (17.1%) |
| 1n (%) | | | |